Traders remain focused on Anktiva’s potential label expansion for papillary bladder cancer, with an FDA decision date set for ...

Saudi Arabia is key to the bull case after ImmunityBio launched Anktiva there for certain patients with bladder and lung ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

Through its Cancer BioShield platform and Anktiva biologic product, ImmunityBio stimulates natural killer cells, cytotoxic T cells, and memory T cells, helping patients fight a growing number of ...

The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of key immune cells—NK and CD8+ killer T cells—that are involved ...

ImmunityBio IBRX shares soared 11.8% in the last trading session to close at $8.71. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...

Adjusted net loss attributable to common stockholders is a non-GAAP financial measure which excludes certain items that are included in net loss attributable to common stockholders, the most directly ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine ...

ImmunityBio (IBRX +2.61%), an immunity-focused biotech, closed Friday’s session at $6.45, down 12.13%. The stock is still up 63.29% in the past five days and 207.14% in the past month. Trading volume ...

Currently, ImmunityBio's flagship Anktiva drug is approved to treat patients with bacillus Calmette-Guérin (BCG)-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) who have Carcinoma in Situ (CIS ...

Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible ...